Bicara Therapeutics Announces Mid-2027 Interim Analysis Timeline and Cash Runway Extension
Bicara Therapeutics (BCAX) has provided updated guidance regarding its clinical development timeline, projecting an interim analysis for its lead program in mid-2027. The company's current cash position of $442.3 million is expected to extend its operational runway into the first half of 2029. Following a leadership transition with the appointment of an interim CEO this fall, management has engaged in extensive discussions with medical professionals. These engagements have reportedly reaffirmed confidence in the potential for the company's therapeutic candidates to provide practice-changing benefits within their target indications.
Tickers: $BCAX